Molecular Mechanism For Resistance To Interferon Therapy
干扰素治疗耐药的分子机制
基本信息
- 批准号:6675119
- 负责人:
- 金额:--
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:
- 资助国家:美国
- 起止时间:至
- 项目状态:未结题
- 来源:
- 关键词:JAK kinase alcoholic liver cirrhosis cytokine receptors drug interactions drug resistance enzyme activity enzyme induction /repression genetically modified animals human tissue immunotherapy infectious hepatitis interferon alpha laboratory mouse liver pharmacology nonhuman therapy evaluation pharmacogenetics protein tyrosine phosphatase tissue /cell culture tumor necrosis factor alpha
项目摘要
Interferon-alpha (IFN-alpha) is currently the primary choice of treatment for chronic viral hepatitis, however, more than 60% of patients respond poorly and heavy drinkers do not respond. Our laboratory is focusing on the host factors that are involved in suppression of IFN signaling and resistance to therapy. We have previously demonstrated that IFN-alpha signaling in the liver is suppressed by multiple host factors, including IL-1, IL-10, TNF-alpha and alcohol drinking. In this year, we have identified that another host factor, IFN-gamma, is also involved in resistance to IFN therapy. We demonstrate that IFN-gamma suppresses IFN-alpha signaling and induces expression of STAT1 in the liver. Overexpression of STAT1 attenuates IFN-alpha signaling in hepatocytes. Furthermore, expression of IFN-alpha signaling components and antiviral proteins in the liver are decreased in chronic alcoholic liver disease. Taken together, our findings suggest that multiple host factors including alcohol contribute to the resistance to IFN-alpha therapy in chronic hepatitis C patients.
干扰素-alpha(IFN-Alpha)目前是慢性病毒肝炎治疗的主要选择,但是,超过60%的患者反应良好,饮酒者不反应。我们的实验室专注于抑制IFN信号传导和对治疗抗性的宿主因素。我们以前已经证明,肝脏中的IFN-Alpha信号被多种宿主因素抑制,包括IL-1,IL-10,TNF-Alpha和饮酒。在今年,我们确定另一个宿主因素IFN-Gamma也参与了对IFN疗法的抗性。我们证明,IFN-GAMMA抑制IFN-α信号传导并诱导肝脏中Stat1的表达。 STAT1的过表达会减弱肝细胞中的IFN-Alpha信号传导。此外,在慢性酒精性肝病中,肝脏中IFN-α信号传导成分和抗病毒蛋白的表达降低。综上所述,我们的发现表明,包括酒精在内的多个宿主因素有助于慢性丙型肝炎患者对IFN-Alpha疗法的抗性。
项目成果
期刊论文数量(3)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Expression of interferon alfa signaling components in human alcoholic liver disease.
干扰素α信号成分在人类酒精性肝病中的表达。
- DOI:10.1053/jhep.2002.31169
- 发表时间:2002
- 期刊:
- 影响因子:0
- 作者:Nguyen,Van-Anh;Gao,Bin
- 通讯作者:Gao,Bin
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
bin gao其他文献
bin gao的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('bin gao', 18)}}的其他基金
TISSUE SPECIFIC CNTRL ALPHA 1B ANDRENOCEPTOR EXPRESSION
组织特异性 CNTRL ALPHA 1B 雄激素受体表达
- 批准号:
2633945 - 财政年份:1998
- 资助金额:
-- - 项目类别:
TISSUE SPECIFIC CNTRL ALPHA 1B ANDRENOCEPTOR EXPRESSION
组织特异性 CNTRL ALPHA 1B 雄激素受体表达
- 批准号:
6172833 - 财政年份:1998
- 资助金额:
-- - 项目类别:
TISSUE SPECIFIC CNTRL ALPHA 1B ANDRENOCEPTOR EXPRESSION
组织特异性 CNTRL ALPHA 1B 雄激素受体表达
- 批准号:
2895764 - 财政年份:1998
- 资助金额:
-- - 项目类别:
Pathogenesis and Novel Therapeutic Targets of Fatty Liver Disease and Cancer
脂肪肝疾病和癌症的发病机制和新的治疗靶点
- 批准号:
10004417 - 财政年份:
- 资助金额:
-- - 项目类别:
Biological Significance and Therapeutic Potential of Cyt
细胞色素的生物学意义和治疗潜力
- 批准号:
6818687 - 财政年份:
- 资助金额:
-- - 项目类别:
相似国自然基金
溶血磷脂酸和1-磷酸鞘氨醇对间充质干细胞临床移植治疗急性肝损伤和酒精性肝硬化效率的影响机制研究
- 批准号:81800525
- 批准年份:2018
- 资助金额:20.0 万元
- 项目类别:青年科学基金项目
酒精性肝硬化的临床流行病学和NK细胞免疫学特征研究
- 批准号:81172779
- 批准年份:2011
- 资助金额:60.0 万元
- 项目类别:面上项目
相似海外基金
Phosphodiesterase 4B Inhibition as a Therapeutic Target for Alcohol-associated Liver Disease
磷酸二酯酶 4B 抑制作为酒精相关性肝病的治疗靶点
- 批准号:
10354185 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Evaluation of anti-fibrotic and anti-inflammatory semi-synthetic oxysterol, Oxy210, as a therapeutic drug candidate for non-alcoholic steatohepatitis
抗纤维化和抗炎半合成氧甾醇 Oxy210 作为非酒精性脂肪性肝炎候选治疗药物的评价
- 批准号:
10697132 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Mechanisms of gut microbiota/metabolite interface-mediated hepatic inflammation
肠道微生物群/代谢物界面介导的肝脏炎症机制
- 批准号:
10678944 - 财政年份:2022
- 资助金额:
-- - 项目类别:
Chronic alcohol consumption results in elevated Autotaxin levels that suppress anti-tumor immunity
长期饮酒会导致自分泌运动因子水平升高,从而抑制抗肿瘤免疫力
- 批准号:
10370159 - 财政年份:2022
- 资助金额:
-- - 项目类别: